Primer: Kalbe Farma (KLBF IJ) - Dec 2025
Kalbe Farma is the largest publicly-listed pharmaceutical company in Indonesia and Southeast Asia, with a diversified business model spanning...
175 Views
Kalbe Farma (KLBF.IJ) 3Q25: In-Line; Broad-Based Revenue Recovery Offsets Margin Pressure...
Broad-based 3Q25 revenue rebound managed to offset margin drag due to higher BPJS pharma, non-dairy mix, and elevated selling expenses.
193 Views
Kalbe Farma (KLBF.IJ) - A Beaten Down Blue Chip; Stable IDR Limits EPS Downside Risk
We view KLBF’s share price decline over the past 3M (-24%) as unwarranted given its resilient 1H25 core profit of +6% yoy vs. peers -7%.
234 Views
Kalbe Farma (KLBF.IJ) Sustainable Moat Underpins Steady Earnings Growth
1Q25 strong earnings were driven by cost-efficiency; we expect 2Q25 revenue to normalize post-Eid yet still on-track to meet FY25F guidance.
376 Views
Kalbe Farma (KLBF IJ) - Increasingly Healthy Recovery
Kalbe Farma booked an impressive set of FY2024, booking healthy growth driven by pharmaceuticals, distribution & Logistics, and consumer health,...
701 Views